
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX is a promising company with a unique focus on using Nucleosomics to develop simple and effective blood tests for early detection and monitoring of a variety of diseases, including cancer. The recent announcement of a high sensitivity rate for early stage cancers in a blinded validation cohort highlights the potential of their technology and its possible applications in Multi-Cancer Early Detection and Minimal Residual Disease detection. Additionally, their focus on circulating cell free nucleoproteins and the potential for partnerships adds further value to the company.
Bears say
VolitionRX is facing a negative outlook due to ongoing concerns about its capital structure and investor confidence, as well as its ability to meet compliance requirements with NYSE American. Additionally, while the company has shown potential through its Nucleosomics platform and partnerships with top diagnostic and liquid biopsy companies, there is still uncertainty surrounding its ability to generate significant revenue and achieve clinical adoption. Other risk factors, such as regulatory and legal risks, also contribute to the negative outlook for the company.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares